Real-world imaging data is medical imaging collected during routine clinical care, such as CT, MRI, X-ray, and ultrasound studies, rather than in a controlled trial. Segmed provides millions of regulatory-grade, de-identified medical images linked with longitudinal, multimodal data that researchers at life sciences and technology companies use to support research, AI development, and regulatory evidence needs.
Segmed licenses real-world medical imaging data through Openda, its data platform. The network spans 2,800+ healthcare partner sites and 150,000,000+ imaging studies, sourced across all 50 U.S. states and 5 continents. Teams in pharmaceuticals, medical devices, and technology can contact Segmed to discuss datasets that fit their research and innovation program.
Segmed is a real-world multimodal data company rooted in medical imaging. It provides millions of regulatory-grade, de-identified medical images, connected to longitudinal, multimodal data such as EHR records and pathology slides, to researchers at life sciences and technology companies for AI development, research, and regulatory evidence.
Segmed's imaging covers the full diagnostic spectrum: CT, MRI, X-ray, and ultrasound, plus hybrid imaging such as PET/CT and PET/MR, DEXA, mammography, echocardiography, and fluorescence. Imaging can also be connected to multimodal data, including EHR records, pathology slides, and non-radiology sources.
Medical AI developers typically need training data and independent, clinically validated datasets that represent the intended patient population, devices, and practice settings. Segmed provides AI training data and FDA/CE regulatory validation datasets through subscription to its database or tailored-made datasets, curated by its Clinical team. More than 50 cutting-edge products have been FDA-cleared using Segmed's data network.
Yes. Segmed's data is de-identified and privacy-preserving. Details on security practices are available on the Security & Compliance page and the Trust Center.
Segmed's data is longitudinal, practice- and device-diverse, and clinically validated. It is sourced from 2,800+ healthcare partner sites, all 50 U.S. states, and 5 continents, which helps teams build and validate AI, diagnosis and therapeutics that reflects real-world variation and reduces bias.
Life sciences, biopharma and technology teams use Segmed's longitudinal data and fit-for-purpose, regulatory-grade multimodal datasets, including millions of tokenized studies, to generate imaging evidence for research programs. Real-world data can also serve as an external control arm.
Openda is Segmed's data platform. It is the central way customers explore and work with Segmed's imaging datasets and find the right evidence for their programs.
Customers include Bayer, Fujifilm, GE Healthcare, Johnson & Johnson, Medtronic, Microsoft, Nucs AI, Onc AI, Philips, Siemens, Smith+Nephew, and Stryker. Case studies include RadUnity's fast track to FDA clearance and NeuroCare.AI's accelerated R&D.
Yes. Healthcare providers can join Segmed's global network of healthcare partners and contribute medical imaging data that supports innovation across the healthcare ecosystem.
Segmed’s network holds 150 million imaging studies, including 58.9M imaging studies across integrated data partners. Teams use it in two ways: to source multi-site, multi-vendor cohorts at scale, or to build a dataset around a specific research program, with custom curation from Segmed’s Clinical team. AI developers preparing FDA or CE submissions also use it for validation datasets. Customers have achieved 50+ FDA clearances through the Segmed data network.
